Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Barinthus Biotherapeutics PLC | BRNS | NASDAQ | Depository Receipt |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.4299 | 06:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.4299 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 1 | 1 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 04:41:13 | 1 | 2.43 | USD |
Barinthus Biotherapeutics PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 94.85M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Barinthus Biotherapeutics
| Date | Time | Source | Heading |
|---|---|---|---|
| 5/15/2024 | 15:07 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/14/2024 | 15:21 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/14/2024 | 15:17 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/14/2024 | 15:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/14/2024 | 15:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/14/2024 | 15:02 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
| 5/13/2024 | 07:13 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/13/2024 | 07:07 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
BRNS Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca. |
